EC
EDIT icon

EntryPoint Capital’s Editas Medicine EDIT Stock Holding History

EntryPoint Capital’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.3K Buy
+26,944
New +$78.7K 0.02% 750
2026
Q1 		– Sell
-84,554
Closed -$173K – 795
2025
Q4 		$173K Buy
+84,554
New +$244K 0.07% 575
2024
Q2 		– Sell
-9,669
Closed -$71.7K – 1517
2024
Q1 		$71.7K Buy
+9,669
New +$80.3K 0.06% 590

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

EntryPoint Capital's EDIT Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Editas Medicine (EDIT) in Q2 2026: 26,944 shares worth $87.3K. The stake represents 0.02% of the portfolio and ranks #750 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in EDIT as recently as Q4 2025.

EntryPoint Capital first reported a position in EDIT in Q1 2024 and has held it in 3 quarters since. The position peaked at $173K in Q4 2025. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • EntryPoint Capital held 26,944 shares of Editas Medicine worth $87.3K as of Q2 2026.
  • Editas Medicine was a new EntryPoint Capital position in Q2 2026.
  • Editas Medicine made up 0.02% of EntryPoint Capital's portfolio in Q2 2026, its #750 holding.
  • EntryPoint Capital first reported a position in Editas Medicine in Q1 2024 and has held it in 3 quarters since.
  • EntryPoint Capital's Editas Medicine position peaked at $173K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.